

Allegato B

Procedura selettiva di chiamata per n. 1 posto di Professore di ruolo di II fascia presso il Dipartimento di Medicina Sperimentale - Facoltà di Medicina e Odontoiatria, GSD 06/MEDS-08 (EX SC 06/D2) – Settore scientifico-disciplinare MEDS-08/A (EX SSD MED/13), indetta ai sensi dell'art. 18, comma 4, della Legge n. 240/2010, Decreto Rettore Università di Roma “La Sapienza” n 207/2025 del 21/01/2025, pubblicata sulla G.U.-quarta serie speciale numero 12 del 11/2/2025 (25E00586), codice bando 2024PAE023.

RICCARDO POFI
Curriculum Vitae

Place OXFORD
Date 18/02/2025

Part I – General Information

Full Name	RICCARDO POFI
Citizenship	ITALIAN
Spoken Languages	Italian (native), English (Advanced, C1, OET Certified)

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,...)
Internship	2009-2012	Sapienza University of Rome	Internship at the Department of Experimental medicine
University graduation	2012	Sapienza university of Rome	MD, Medicine and Surgery (110 cum laude/110). Research thesis titled: "Pathophysiology of diabetic cardiomyopathy in Diabetes Mellitus Type 2. Prospective longitudinal study on the progression of heart damage and identification of new markers of disease."
Research Fellowship	2017-2019	Oxford University	Research fellowship at the Oxford Centre for Diabetes Endocrinology and Metabolism focusing on development of new strategies for assessing and predicting HPA axis recovery in patients affected by reversible causes of adrenal insufficiency; assessing the differential contribution of different doses of exogenous steroids on immune, cardiovascular and metabolic system with high throughput pioneering analyses. Tutor Prof. Jeremy Tomlinson.
Specialty	2018	Sapienza University of Rome	70 cum laude/70 in Endocrinology and Metabolic Diseases (70 cum laude/70). Supervisors: Prof. Andrea M. Isidori (“Sapienza” University of Rome) and Prof Jeremy W. Tomlinson (Oxford

			University). Thesis title: “The short Synacthen (corticotropin) test can be used to predict recovery of hypothalamo-pituitary-adrenal axis function.
PhD	2021	Sapienza University of Rome	Cum laude and special mention of Doctor Europaeus. PhD in Endocrinological, Metabolic and Andrological Sciences. Supervisor Prof. Elisa Giannetta (Sapienza University of Rome) and Jeremy W. Tomlinson (Oxford University). Title of research: “Defining and predicting the adverse effects of prescribed steroids”.
Licensure 01	2013	Ordine dei Medici di Frosinone	Registration to Italians medical board; license to practice Medicine as doctor (number FR3920)
Licensure 02	2022	General Medical Council (UK)	Registration to the UK medical board; license to practice Medicine and Endocrinology (7989673)
Scientific qualification	2022	Italian Ministry of University and Research	Scientific National Qualification (Art. 16 of the law 30 December 2010, n.240 – abilitazione scientifica nazionale ASN) Associate professor in Endocrinology MED13

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
2022	now	Oxford University	Clinical Research Fellow – Sub-investigator of the DC-MACS trial: “ <i>Dissecting the Contribution of glucocorticoid metabolism in Mild Autonomous Cortisol Secretion: a randomised controlled trial of the 11β-HSD1 inhibitor SPI-62.</i> ”

IIIB – Other Appointments

Start	End	Institution	Position
2021	Now	Italian Society of Endocrinology	Member of the National Scientific Commission of the Young Italian Endocrinologist (EnGioI).
2023	Now	Italian Society of Endocrinology	Coordinator of the Cardiovascular Endocrinology Club of the Italian Society of Endocrinology
2023	Now	Frontiers in Endocrinology	Associate editor, section of Adrenal Endocrinology

2022	Now	National Health System (NHS) trust UK	Honorary Clinician in Endocrinology and Diabetology for outpatients' clinics for adrenal and pituitary diseases, including rare disease such as: Congenital Adrenal Hyperplasia.
------	-----	---------------------------------------	--

Part IV – Teaching experience

Year	Institution	Lecture/Course
2023-2024	UNIVERSITY OF ATHENS	Lecturer in the postgraduate course "Endocrine Neoplasia" for post-doc students of the University of Athens.

Part V - Society memberships, Awards and Honors

Year	Title
2012	Membership - Italian Society of Endocrinology (SIE)
2014	Membership - American “Endocrine Society”
2016	Membership - European Society of Endocrinology (ESE)
2016	Membership - European NeuroEndocrine Association” (ENEA)
2017	Membership - Italian Society of Diabetes” (SID)
2018	Membership - European Academy of Andrology (EAA)
2018	Membership - British Endocrine Society (BES)
2020	Membership - member of the Global Burden of Disease (GBD) Collaborator Network
Awards	
2018	Winner of Exchange in Endocrinology Expertise of the European Union of Medical Specialists (UEMS)
2018	Winner of the Short-Term Fellowship grant of the European Society of Endocrinology (ESE)
2019	Winner of a participation to attend the European Multidisciplinary Course of Pituitary Tumors (EuroPit) awarded by the European Society of Endocrinology
2019	Winner of a participation to attend the Pituitary Masterclass in Milan awarded by the European Society of Endocrinology
2020	Winner of the International Mobility Program of PhD students in the Sapienza University of Rome
2021	Winner of the best oral presentation in the Diabetes Session of the international conference of “ESE Young Endocrinologists and Scientists
2021	Winner of the best oral presentation of the international conference of “ESE Young Endocrinologists and Scientists
2018-2019	Winner of several national and international travel grants including: - 2018 to attend the European Society of Endocrinology (ESE) meeting in Barcelona; - 2018 to attend the International Society of Endocrinology (ISE) meeting in Cape Town; - 2018-2019 to attend the British Endocrine Society (BES) meeting in Glasgow, Brighton; - 2019 to attend the EYES meeting in Athens;

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2021	“Effects of 5 alpha-Reductase Inhibitors on glucose metabolism in patients with BPH and Type 2 diabetes mellitus.”	Bando Ateneo – Sapienza University of Rome - Call for research proposal - PI	2.000 €
2021	“Steroid treatment for adrenal rest tumours – START protocol. “	Bando Ateneo – Sapienza University of Rome - Investigator	3000 €
2025	Reshaping The Landscape of the 11 beta HSD System In Androgen Metabolism Kinetics (Re-ThInK)	Fondo Italiano per la Scienza (FIS 2) - PI	1.323.601 €

Part VII – Research Activities

Keywords	Brief Description
Glucocorticoid metabolism	My research integrates <i>clinical trials, translational endocrinology, and biomarker development to improve diagnostic and therapeutic strategies for endocrine disorders</i> . I have extensively studied <i>glucocorticoid metabolism, endocrine-metabolic interactions, and drug repurposing</i> , with a particular focus on <i>how hormonal rhythms influence metabolism and disease progression</i> .
Circadian rhythms	
Adrenal disorders	
Drug repurposing	A significant part of my work has been dedicated to understanding the <i>interplay between circadian regulation, endocrine disorders, and metabolic health</i> . My studies on mild autonomous cortisol secretion (MACS) have revealed sex-specific metabolic consequences, particularly the increased thrombotic risk in women (JES 2024). These findings underscore the importance of hormonal rhythms in metabolic homeostasis and have redefined our understanding of endocrine disease progression. Additionally, I contributed to a multicentre clinical trial demonstrating how circadian disruption in chronic endogenous hypercortisolism profoundly alters immune oscillation, leading to significant changes in peripheral blood mononuclear cell populations and clock gene expression (EBioMedicine 2024). This study established immune profiling as a novel biomarker for hypercortisolism activity, paving the way for chronobiological interventions in endocrine diseases. In recognition of my expertise, I was <i>invited by Endocrine Reviews</i> to lead a comprehensive review on “Separating the beneficial from the adverse effects of exogenous glucocorticoids.” This publication was honored with inclusion in the “Endocrine Society Thematic Issue on Adrenal Disease 2024” and is now <i>the most cited article of 2024</i> , with 68 citations and over 10,000 downloads, highlighting its impact on the scientific community.
Biomarker development	
Endocrine diagnostics	
Cardiovascular endocrinology	My research in <i>steroid hormone metabolism and drug repurposing</i> has centered on the clinical application of phosphodiesterase-5 inhibitors (PDE5i) and the role of 11β-HSD1 inhibition in mitigating glucocorticoid-induced metabolic complications. I have been deeply involved in translational research, bridging clinical observations with laboratory models to generate new hypotheses and discoveries. My early work focused on the pathophysiology of diabetic complications, where I investigated the therapeutic potential of PDE5i. This included a meta-analysis revealing their cardioprotective and anti-remodeling properties (BMC Medicine 2014), as well as two original translational studies demonstrating their role in reducing inflammation and epicardial fat dysfunction in vascular complications of diabetes (PLoS One, 2015; JCEM, 2016). Expanding on these findings, I explored the role of PDE5i in diabetic end-organ damage, translating clinical insights into animal models of diabetic nephropathy, where I identified the miR-22/BMP7 axis as a novel therapeutic target (Nature Scientific Reports, 2017). Recognizing inconsistencies in published data on

the protective role of PDE5i in diabetic complications, I led the first randomized controlled trial demonstrating the sex- and tissue-specific effects of PDE5 inhibition in diabetic cardiomyopathy. This landmark study was published in Science Translational Medicine (2022), providing a new perspective on the therapeutic potential of PDE5i in endocrine-metabolic disorders.
My work has also advanced our <i>understanding of glucocorticoid metabolism and its clinical implications</i> . As a sub-investigator in the NBI-74788-CAH3003 trial at Sapienza University of Rome, I contributed to evaluating Crinecerfont in adults with congenital adrenal hyperplasia (NEJM 2024). Subsequently, my research in Oxford led to the TICS1 trial, published in Nature Communications (2024), which investigated 11 β -HSD1 inhibition as a strategy to mitigate prednisolone-induced side effects. This study demonstrated that selective 11 β -HSD1 inhibition significantly reduced glucocorticoid-related adverse effects without compromising the desired immunosuppressive actions, a finding with profound clinical implications, particularly for patients with autoimmune diseases. This body of work reflects my commitment to translating mechanistic insights into actionable clinical strategies that improve patient outcomes.
Beyond drug repurposing, my research has led to the <i>development of innovative diagnostic and prognostic tools</i> for adrenal and pituitary disorders. I developed and validated predictive models for hypothalamic-pituitary-adrenal (HPA) axis recovery, offering clinicians practical tools to guide repeat testing frequency and inform patients about their likelihood of regaining HPA axis function. These models, the first of their kind, were published in JCEM (2018, 2019). Additionally, I contributed to predictive data for postoperative hypocortisolism in patients with non-ACTH-secreting pituitary adenomas and developed ICARO, a pioneering questionnaire for stratifying infection risk in patients receiving long-term glucocorticoid therapy (EJE 2022). In Oxford, I led the clinicians involved in the diagnosis of adrenal diseases to further refine the diagnostic accuracy in Cushing's syndrome, creating an algorithm currently use in our department and that enhances current screening tools (JEI 2024). Furthermore, I co-authored the development of a microneedle-based nanoporous gold electrochemical biosensor for real-time catecholamine detection, representing a major advancement in minimally invasive endocrine diagnostics.
My <i>international experience</i> spans both research and clinical practice. I currently serve as a Clinical Research Fellow at the University of Oxford, where I am a sub-investigator in the DC-MACS trial, and I hold a clinical appointment as an Endocrinology and Diabetes Specialist within the National Health System (NHS) trust in the UK, providing expertise in managing adrenal, pituitary, and metabolic disorders.
My <i>leadership in endocrinology</i> extends to academic and public engagement. As coordinator of the Cardiovascular Endocrinology Club within the Italian Society of Endocrinology (SIE), I actively promote scientific dissemination and translational research on steroid-induced metabolic diseases. Additionally, I have contributed to clinical guidelines, including COVID-19 glucocorticoid management guidelines published in The Lancet Diabetes & Endocrinology (2022 and 2020) and in JEI (2020).
Recently, I secured a <i>highly competitive Italian Science Fund 2022–2023</i> (FIS 2 – Call) research grant of €1,323,601 to support fundamental research activities. With this funding, I am establishing an independent research group focused on advancing personalized medicine in endocrinology, particularly through innovative diagnostic and therapeutic strategies. This achievement reflects my long-term commitment to pioneering research that bridges fundamental science with clinical applications, driving innovation in endocrine and metabolic health.

Part VII b – Activities of Third Mission

Year	Activity	Role
2009	Campus Health ONLUS – Health, Sport and Solidarity for Promotion and Dissemination of the culture of Primary Prevention of Diseases Through the initiative to health , cultural, educational and scientific.	Participant in the Health Campus in Rome.
2009-2018	Participation in the Research Project funded by the National Center for Disease Prevention and Control (Ccm) "Prevention in Andrology – AmicoAndrologo Campaign" (2009-2011).	Participant in the local activities in schools across Rome and Lazio.

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	81	Pubmed	2014	2025
Books [teaching]	2	Harrison principle of internal medicine. Curatela. ISBN 978-88-08-82037-2;	2021	2021
		“Manuale di endocrinologia, introduzione alla patologia surrenalica.” Chapter: “Introduzione alla patologia surrenalica”. Edited by Carocci - Faber ISBN 978-88-746-6969-1;	2023	

Total Impact factor	542.687
Total Citations	1836 (Scopus)
Average Citations per Product	22.66
Hirsch (H) index	26 (Scopus)
Normalized H index*	2.36

*H index divided by the academic seniority.

Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

N°	Title	Authors	Reference data	Journal IF	Citations (scopus)
1	<u>Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial.</u>	Pofi R* , Giannetta E*, Feola T, Galea N, Barbagallo F, Campolo F, Badagliacca R, Barbano B, Ciolina F, Defeudis G, Filardi T, Sesti F, Minnetti M, Vizza CD, Pasqualetti P, Caboni P, Carbone I, Francone M, Catalano C, Pozzilli P, Lenzi	<i>Sci Transl Med.</i> 2022 Jun 15;14(649):eabl8503. doi: 10.1126/scitranslmed.abl8503. Epub 2022 Jun 15. PMID:	17.992	33

		A, Venneri MA, Gianfrilli D, Isidori AM. *Shared first authorship	35704597 Clinical Trial.		
<u>2</u>	<u>Diabetic Cardiomyopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix: A 5-Year Prospective Study.</u>	Pofi R* , Giannetta E*, Galea N, Francone M, Campolo F, Barbagallo F, Gianfrilli D, Venneri MA, Filardi T, Cristini C, Antonini G, Badagliacca R, Frati G, Lenzi A, Carbone I, Isidori AM. *Shared first authorship	JACC Cardiovasc Imaging. 2020 Nov 18:S1936-878X(20)30916-5. doi: 10.1016/j.jcmg.2020.10.009. Online ahead of print. PMID: 33221242	12.740	39
<u>3</u>	<u>Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool.</u>	Minnetti M, Hasenmajer V, Sbardella E, Angelini F, Simeoli C, Di Paola N, Cozzolino A, Pivonello C, De Alcubierre D, Chiloiro S, Baldelli R, De Marinis L, Pivonello R, Pofi R* , Isidori AM*. *Shared senior authorship and co-corresponding authorship	Eur J Endocrinol. 2022 Oct 13;187(5):719-731. doi: 10.1530/EJE-22-0454. Print 2022 Nov 1. PMID: 36102827	6.664	19
<u>4</u>	<u>11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.</u>	Othonos N, Pofi R , Arvaniti A, White S, Bonaventura I, Nikolaou N, Moolla A, Marjot T, Stimson RH, van Beek AP, van Faassen M, Isidori AM, Bateman E, Sadler R, Karpe F, Stewart PM, Webster C, Duffy J, Eastell R, Gossiel F, Cornfield T, Hodson L, Jane Escott K, Whittaker A, Kirik U, Coleman RL, Scott CAB, Milton JE, Agbaje O, Holman RR, Tomlinson JW.	Nature Commun. 2023 Feb 23;14(1):1025. doi: 10.1038/s41467-023-36541-w. PMID: 36823106	14.919	15
<u>5</u>	<u>Treating the Side Effects of Exogenous Glucocorticoids: Can We Separate the Good From the Bad?</u>	Pofi R , Caratti G, Ray DW, Tomlinson JW.	Endocr Rev. 2023 Nov 9;44(6):975-1011. doi: 10.1210/endrev/bnad016. PMID: 37253115	20.3	61 <i>Selected as the most cited article in Endocrine review 2024</i>
<u>6</u>	<u>Predicting postoperative hypocortisolism in patients with non-aldosterone-producing adrenocortical adenoma: a retrospective single-centre study.</u>	Bonaventura I, Tomaselli A, Angelini F, Ferrari D, De Alcubierre D, Hasenmajer V, Sbardella E, Cozzolino A, Paganini AM, Isidori AM, Minnetti M, Pofi R .	J Endocrinol Invest. 2024 Feb 22. doi: 10.1007/s40618-023-02283-1. PMID: 38386266	5.4	2

7	<u>Development of diagnostic algorithm for Cushing's syndrome: a tertiary centre experience.</u>	Efthymiadis A, Loo H, Shine B, James T, Keevil B, Tomlinson JW, Pal A, Pofi R .	J Endocrinol Invest. 2024 Mar 27. doi: 10.1007/s40618-024-02354-x. PMID: 38536658	5.4	
8	<u>Impact of Female Sex and Mild Cortisol Secretion on Coagulation Profile in Adrenal Incidentalomas.</u>	Bonaventura I, Minnetti M, Ferrari D, Hasenmajer V, Tomaselli A, De Alcubierre D, Lenzi A, Pofi R* , Isidori AM*. *Shared senior authorship and co-corresponding authorship	J Endocr Soc. 2024 Dec 12;9(1):bvae215 . doi: 10.1210/jendso/bvae215. PMID: 39669652	3.2	
9	<u>Circadian clock disruption impairs immune oscillation in chronic endogenous hypercortisolism: a multi-level analysis from a multicentre clinical trial.</u>	Hasenmajer V, Sbardella E, Sciarra F, Simeoli C, Pivonello C, Ceccato F, Pofi R , Minnetti M, Rizzo F, Ferrari D, Bonaventura I, Barbagallo F, Giannetta E, Alunni Fegatelli D, Conia S, Navigli R, Arnaldi G, Scaroni C, Pivonello R, Gianfrilli D, Venneri MA, Isidori AM.	EBioMedicine. 2024 Dec;110:105462 . doi: 10.1016/j.ebiom.2024.105462. Epub 2024 Nov 28. PMID: 39612654	9.2	
10	<u>Multivariate Model to predict Stimulation Test to Diagnose Adrenal Insufficiency Using Previous Test Results.</u>	Lawrence NR, Arshad MF, Pofi R , Ashby S, Dawson J, Tomlinson JW, Newell-Price J, Ross RJ, Elder CJ, Debono M. Multivariable Model to Predict an ACTH	J Endocr Soc. 2023 Oct 7;7(12):bvad127 . doi: 10.1210/jendso/bvad127. PMID:3794229 2;	4.1	3
11	<u>Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids.</u>	Othonos N, Marjot T, Woods C, Hazlehurst JM, Nikolaou N, Pofi R , White S, Bonaventura I, Webster C, Duffy J, Cornfield T, Moolla A, Isidori AM, Hodson L, Tomlinson JW.	J Clin Endocrinol Metab. 2020 Sep 1;105(9):dgaa408. doi: 10.1210/clinem/dgaa408. PMID: 32594135	5.605	10
12	<u>Microneedle-based nanoporous gold electrochemical sensor for real-time catecholamine detection.</u>	Tortolini C, Cass AEG, Pofi R , Lenzi A, Antiochia R.	Mikrochim Acta. 2022 Apr 7;189(5):180. doi: 10.1007/s00604-022-05260-2. PMID:3539157 1	5.833	24

Part X– Total list of publications

		IF By-year
1.	<u>Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.</u> Pofi R , Fiore D, De Gaetano R, Panio G, Gianfrilli D, Pozza C, Barbagallo F, Xiang YK, Giannakakis K, Morano S, Lenzi A, Naro F, Isidori AM, Venneri MA. Sci Rep. 2017 Mar 15;7:44584. doi: 10.1038/srep44584. PMID: 28294194	5.525

2.	<u>Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.</u> Giannetta E, Feola T, Gianfrilli D, Pofi R , Dall'Armi V, Badagliacca R, Barbagallo F, Lenzi A, Isidori AM. BMC Med. 2014 Oct 20;12:185. doi: 10.1186/s12916-014-0185-3. PMID:25330139	7.249
3.	<u>The short Synacthen (corticotropin) test can be used to predict recovery of hypothalamo-pituitary-adrenal axis function</u> Pofi R , Feliciano C, Sbardella E, Argese N, Woods CP, Grossman AB, Jafar-Mohammadi B, Gleeson H, Lenzi A, Isidori AM, Tomlinson JW. JCEM. 2018 May 25. jc.2018-00529. https://doi.org/10.1210/jc.2018-00529	5.455
4.	<u>Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study.</u> Venneri MA, Hasenmajer V, Fiore D, Sbardella E, Pofi R , Graziadio C, Gianfrilli D, Pivonello C, Negri M, Naro F, Grossman AB, Lenzi A, Pivonello R, Isidori AM. JCEM. 2018 May 25. jc.2018-00346. https://doi.org/10.1210/jc.2018-00346	5.455
5.	<u>The women's heart: insights into new potential targeted therapy.</u> Gianfrilli D, Pofi R , Feola T, Lenzi A, Giannetta E. Curr Med Chem. 2016 Nov 18. [Epub ahead of print] PMID:27855624	3.455
6.	<u>Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies.</u> Pofi R , Di Mario F, Gigante A, Rosato E, Isidori AM, Amoroso A, Cianci R, Barbano B. Curr Drug Metab. 2016;17(5):497-502. Review. PMID:27025881	2.847
7.	<u>PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial.</u> Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, di Dato C, Pofi R , Pozza C, Sbardella E, Carbone I, Naro F, Lenzi A, Venneri MA, Isidori AM. J Clin Endocrinol Metab. 2016 Apr;101(4):1525-34. doi: 10.1210/jc.2015-4252. Epub 2016 Mar 10. PMID:26964730	5.531
8.	<u>Erectile dysfunction and its management in patients with diabetes mellitus.</u> Defeudis G, Gianfrilli D, Di Emidio C, Pofi R , Tuccinardi D, Palermo A, Lenzi A, Pozzilli P. Rev Endocr Metab Disord. 2015 Oct 26. [Epub ahead of print] PMID:26497842	5.088.
9.	<u>Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?</u> Pofi R , Gianfrilli D, Badagliacca R, Di Dato C, Venneri MA, Giannetta E. J Endocrinol Invest. 2016 Feb;39(2):131-42. doi: 10.1007/s40618-015-0339-y. Epub 2015 Jul 5. Review. PMID:26142740	1.994
10.	<u>A prospective study on contrast-enhanced magnetic resonance imaging of testicular lesions: distinctive features of Leydig cell tumours.</u> Manganaro L, Vinci V, Pozza C, Saldari M, Gianfrilli D, Pofi R , Bernardo S, Cantisani V, Lenzi A, Scialpi M, Catalano C, Isidori AM. Eur Radiol. 2015 Dec;25(12):3586-95. doi: 10.1007/s00330-015-3766-4. Epub 2015 May 17. PMID:25981218	3.640
11.	<u>Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice.</u> Venneri MA, Giannetta E, Panio G, De Gaetano R, Gianfrilli D, Pofi R , Masciarelli S, Fazi F, Pellegrini M, Lenzi A, Naro F, Isidori AM. PLoS One. 2015 May 11;10(5):e0126580. doi: 10.1371/journal.pone.0126580. eCollection 2015. PMID:25961566	3.540
12.	<u>Hypothyroidism and nephrotic syndrome: why, when and how to treat.</u> Di Mario F, Pofi R , Gigante A, Rivoli L, Rosato E, Isidori AM, Cianci R, Barbano B. Curr Vasc Pharmacol. 2017 Feb 7. doi: 10.2174/1570161115999170207114706. PMID:28176633	2.374

13.	<u>Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology.</u> Gianfrilli D, Pierotti S, Pofi R , Leonardo C, Ciccariello M, Barbagallo F. Biomed Res Int. 2014;2014:464869. doi: 10.1155/2014/464869. Epub 2014 Aug 13. PMID:25184140	2.134
14.	<u>Differential diagnosis of nonpalpable testicular lesions: qualitative and quantitative contrast-enhanced US of benign and malignant testicular tumors.</u> Isidori AM, Pozza C, Gianfrilli D, Giannetta E, Lemma A, Pofi R , Barbagallo F, Manganaro L, Martino G, Lombardo F, Cantisani V, Franco G, Lenzi A. Radiology. 2014 Nov;273(2):606-18. doi: 10.1148/radiol.14132718. Epub 2014 Jun 26. PMID:24968192	6.798
15.	<u>BMI, nephroangiosclerosis and glomerulonephritis: is there any meeting point?</u> Gigante A, Giannakakis K, Di Mario F, Barbano B, Rosato E, Pofi R , Di Paolo M, Rocca AR, Cianci R. Nephrology (Carlton). 2017 Aug 17. doi: 10.1111/nep.13155. PMID: 28817218	1.563
16.	<u>Malnutrition is prevalent in patients with cardiorenal syndrome and negatively influences clinical outcome.</u> Gigante A, Rosato E, Barbano B, Di Mario F, Di Lazzaro-Giraldi G, Gasperini ML, Pofi R , Laviano A. J Biol Regul Homeost Agents. 2018 Jan-Feb;32(1):163-166. PMID: 29504382	4.101
17.	<u>Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas.</u> Sbardella E, Minnetti M, D'Aluisio D, Rizza L, Di Giorgio MR, Vinci F, Pofi R , Giannetta E, Venneri MA, Vestri A, Morelli S, Lenzi A, Isidori AM. Eur J Endocrinol. 2018 Mar 6. pii: EJE-17-0986. doi: 10.1530/EJE-17-0986. PMID:29510982	1.469
18.	<u>Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report.</u> Giannetta E, Isidori AM, Durante C, Di Gioia C, Longo F, Tombolini V, Bulzonetti N, Graziadio C, Pofi R , Gianfrilli D, Verrienti A, Carletti R, Filetti S, Lenzi A, Baroli A. Medicine (Baltimore). 2017 Feb;96(6):e5621. doi: 10.1097/MD.0000000000005621. PMID:28178124	4.256
19.	<u>Nutritional status and intrarenal arterial stiffness in cardiorenal syndrome: a pilot study.</u> Gigante A, Di Mario F, Barbano B, Rosato E, Di Lazzaro Giraldi G, Pofi R , Gasperini ML, Amoroso D, Cianci R, Laviano A. Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):313-316. PMID:28165555	1.575
20.	<u>Changes in left ventricular repolarization after short-term testosterone replacement therapy in hypogonadal males.</u> Piccirillo G, Moscucci F, Pofi R , D'Alessandro G, Minnetti M, Isidori AM, Francomano D, Lenzi A, Puddu PE, Alexandre J, Magri D, Aversa A. J Endocrinol Invest. 2019 Mar 5. doi: 10.1007/s40618-019-01026-5. [Epub ahead of print] PMID:30838540	3.166
21.	<u>Clinical presentation, management and follow-up of 83 patients with Leydig cell tumors of the testis: a prospective case-cohort study.</u> Pozza C, Pofi R , Tenuta M, Tarsitano MG, Sbardella E, Fattorini G, Cantisani V, Lenzi A, Isidori AM, Gianfrilli D and the TESTIS UNIT. Hum Reprod. 2019 Aug 1;34(8):1389-1403. doi: 10.1093/humrep/dez083. PMID: 31532522	4.949
22.	<u>Glucocorticoids in pregnancy.</u> Pofi R , Tomlinson JW. Obstet Med. 2020 Jun;13(2):62-69. doi: 10.1177/1753495X19847832. Epub 2019 Jun 9. PMID: 32714437	1.150

23. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, Mariani S, Lubrano C, Poggiogalle E, Migliaccio S, Donini LM, Basciani S, Cignarelli A, Conte E, Ceccarini G, Bogazzi F, Cimino L, Condorelli RA, La Vignera S, Calogero AE, Gambineri A, Vignozzi L, Prodam F, Aimaretti G, Linsalata G, Buralli S, Monzani F, Aversa A, Vettor R, Santini F, Vitti P, Gnessi L, Pagotto U, Giorgino F, Colao A, Lenzi A; **Cardiovascular Endocrinology Club of the Italian Society of Endocrinology.** J Endocrinol Invest. 2019 May 20. doi: 10.1007/s40618-019-01061-2. PMID: 31111407 3.166
24. Recovery of the hypothalamo-pituitary-adrenal axis after trans-sphenoidal surgery for non-ACTH secreting macro adenomas. **Pofi R**, Gunatilake S, Macgregor V, Shine B, Joseph R, Grossman AB, Isidori AM, Cudlip S, Jafar-Mohammadi B, Tomlinson JW, Pal A. JCEM, accepted on June 17, 2019. 5.789
25. Plasma renin measurements are unrelated to mineralocorticoid replacement dose in patients with primary adrenal insufficiency. **Pofi R**, Prete A, Thornton-Jones V, Bryce J, Ali SR, Faisal Ahmed S, Balsamo A, Baronio F, Cannuccia A, Guven A, Guran T, Darendeliler F, Higham C, Bonfig W, de Vries L, Bachega TASS, Miranda MC, Mendonca BB, Iotova V, Korbonits M, Krone NP, Krone R, Lenzi A, Arlt W, Ross RJ, Isidori AM, Tomlinson JW. JCEM, 2019 Oct 16. doi: 10.1210/clinem/dgz055. PMID: 31613957 5.605
26. A Novel MAX Gene Mutation Variant in a Patient With Multiple and "Composite" Neuroendocrine-Neuroblastic Tumors. Pozza C, Sesti F, Di Dato C, Sbardella E, **Pofi R**, Schiavi F, Bonifacio V, Isidori AM, Faggiano A, Lenzi A, Giannetta E. Front Endocrinol (Lausanne). 2020 May 19;11:234. doi: 10.3389/fendo.2020.00234. eCollection 2020. PMID: 32508744 3.519
27. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, Faggiano A; **NIKE group.** Endocrine. 2020 May 28. doi: 10.1007/s12020-020-02331-3. Online ahead of print. PMID: 32468269 3.878
28. Testicular ultrasound (TU) score: a new proposal for a scoring system to predict testicular function. Pozza C, Kanakis G, Carlomagno F, Lemma A, **Pofi R**, Tenuta M, Minnetti M, Tarsitano M, Sesti F, Paoli D, Anzuini A, Lenzi A, Isidori AM, Gianfrilli D. Andrology. 2020 May 23. doi: 10.1111/andr.12822. Online ahead of print. PMID: 32445591 3.259
29. Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy. Minnetti M, Hasenmajer V, **Pofi R**, Venneri MA, Alexandraki KI, Isidori AM. J Endocrinol. 2020 May 1:JOE-20-0066.R2. doi: 10.1530/JOE-20-0066. Online ahead of print. PMID: 32380472 Review. 4.381
30. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, **Pofi R**, Hasenmajer V, Venneri MA, Sbardella E, Simeoli C, Scaroni C, Lenzi A. J Endocrinol Invest. 2020 Apr 25:1-7. doi: 10.1007/s40618-020-01266-w. Online ahead of print. PMID: 32335855. 3.166
31. Late effects of parasellar lesion treatment: hypogonadism and infertility. Sbardella E, Minnetti M, **Pofi R**, Cozzolino A, Greco E, Gianfrilli D, Isidori AM. Neuroendocrinology. 2020 Apr 24. doi: 10.1159/000508107. Online ahead of print. PMID: 32335548 3.392

32. Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection. 24.540
Isidori AM, **Pofi R**, Hasenmajer V, Lenzi A, Pivonello R.
Lancet Diabetes Endocrinol. 2020 Jun;8(6):472-473. doi: 10.1016/S2213-8587(20)30149-2. Epub 2020 Apr 23.
PMID: 32334645
33. Predictors of malignancy in high-risk indeterminate (TIR3B) cytopathology thyroid nodules. 3.166
Cozzolino A, Pozza C, **Pofi R**, Sbardella E, Faggiano A, Isidori AM, Giannetta E, Pernazza A, Rullo E, Ascoli V, Lenzi A, Gianfrilli D.
J Endocrinol Invest. 2020 Feb 25. doi: 10.1007/s40618-020-01200-0. Online ahead of print. PMID: 32100197
34. Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia. 3.259
Tenuta M, Tarsitano MG, Mazzotta P, Lucchini L, Sesti F, Fattorini G, Pozza C, Olivieri V, Naro F, Gianfrilli D, Lenzi A, Isidori AM, **Pofi R**.
Andrology. 2020 Feb 23. doi: 10.1111/andr.12775. Online ahead of print.
PMID: 32090492
35. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. 2.860
Isidori AM, Giannetta E, **Pofi R**, Venneri MA, Gianfrilli D, Campolo F, Mastroianni CM, Lenzi A, d'Ettorre G. Andrology. 2020 Jun 11:10.1111/andr.12837. doi: 10.1111/andr.12837. Online ahead of print. PMID: 32526061
36. Co-administration of 5 α -reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. 5.605
Othonos N, Marjot T, Woods C, Hazlehurst JM, Nikolaou N, **Pofi R**, White S, Bonaventura I, Webster C, Duffy J, Cornfield T, Moolla A, Isidori AM, Hodson L, Tomlinson JW.
J Clin Endocrinol Metab. 2020 Sep 1;105(9):dgaa408. doi: 10.1210/clinem/dgaa408. PMID: 32594135
37. Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. 2.860
Sesti F, **Pofi R**, Minnetti M, Tenuta M, Gianfrilli D, Isidori AM.
Andrology. 2020 Jul 31. doi: 10.1111/andr.12876. Online ahead of print.
PMID: 32737921
38. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 5.516
Vitale G, Dicitore A, Barrea L, Sbardella E, Razzore P, Campione S, Faggiano A, Colao A; NIKE, Albertelli M, Altieri B, Bottiglieri F, De Cicco F, Di Molfetta S, Fanciulli G, Feola T, Ferone D, Ferraù F, Gallo M, Giannetta E, Grillo F, Grossrubatscher E, Guadagno E, Guarnotta V, Isidori AM, Lania A, Lenzi A, Calzo FL, Malandrino P, Messina E, Modica R, Muscogiuri G, Pes L, Pizza G, **Pofi R**, Puliani G, Rainone C, Rizza L, Rubino M, Ruggieri RM, Sesti F, Venneri MA, Zatelli MC.
Rev Endocr Metab Disord. 2020 Sep 15. doi: 10.1007/s11154-020-09589-y. Online ahead of print. PMID: 32935263 Review.
39. Cardiovascular complications in patients with Klinefelter's syndrome. 2.412
Sesti F, **Pofi R**, Pozza C, Minnetti M, Gianfrilli D, Kanakis GA.
Curr Pharm Des. 2020 Nov 1. doi: 10.2174/1381612826666201102105408. Online ahead of print.
PMID: 33138758
40. Diabetic Cardiomyopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix: A 5-Year Prospective Study. 12.740
Pofi R, Giannetta E, Galea N, Francone M, Campolo F, Barbagallo F, Gianfrilli D, Venneri MA, Filardi T, Cristini C, Antonini G, Badagliacca R, Frati G, Lenzi A, Carbone I, Isidori AM.
JACC Cardiovasc Imaging. 2020 Nov 18:S1936-878X(20)30916-5. doi: 10.1016/j.jcmg.2020.10.009. Online ahead of print.
PMID: 33221242

41.	<u>Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study.</u>	5.605
	Puliani G, Hasenmajer V, Sciarra F, Barbagallo F, Sbardella E, Pofi R , Gianfrilli D, Romagnoli E, Venneri MA, Isidori AM. J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2215-e2227. doi: 10.1210/clinem/dgab038. PMID: 33484559	
42.	<u>Eco-Friendly Biosensing Development.</u>	4.034
	Tortolini C, Capecchi E, Tasca F, Pofi R , Venneri MA, Saladino R, Antiochia R. Nanomaterials (Basel). 2021 Mar 12;11(3):718. doi: 10.3390/nano11030718. PMID: 33809211	
43.	<u>Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask.</u>	3.675
	Albertelli M, Grillo F, Lo Calzo F, Puliani G, Rainone C, Colao AAL, Faggiano A; NIKE group . Front Endocrinol (Lausanne). 2021 Apr 23;12:680305. doi: 10.3389/fendo.2021.680305. eCollection 2021. PMID: 33967966	
44.	<u>Use of contrast enhanced ultrasound in testicular diseases: A comprehensive review.</u>	2.860
	Tenuta M, Sesti F, Bonaventura I, Mazzotta P, Pofi R , Gianfrilli D, Pozza C. Andrology. 2021 May 27. doi: 10.1111/andr.13057. Online ahead of print. PMID: 34043256	
45.	<u>A clinical approach to parasellar lesions in the transition age.</u>	3.392
	Sbardella E, Puliani G, Feola T, Pofi R , Pirchio R, Sesti F, Verdecchia F, Gianfrilli D, Moffat D, Isidori AM, Grossman AB; Talent group. J Neuroendocrinol. 2021 Jun;33(6):e12995. doi: 10.1111/jne.12995. PMID: 34138496	
46.	<u>Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management.</u>	5.555
	Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Colao A, Faggiano A; NIKE Group . Front Endocrinol (Lausanne). 2021 Jun 18;12:700806. doi: 10.3389/fendo.2021.700806. eCollection 2021. PMID: 34220723	
47.	<u>Testicular microvascular flow is altered in Klinefelter syndrome and predicts circulating testosterone.</u>	5.958
	Carlomagno F, Pozza C, Tenuta M, Pofi R , Tarani L, Sesti F, Minnetti M, Gianfrilli D, Isidori AM. J Clin Endocrinol Metab. 2021 Aug 18;dgab605. doi: 10.1210/clinem/dgab605. Online ahead of print. PMID: 34407199	
48.	<u>Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes.</u>	4.807
	Campolo F, Pofi R , Venneri MA, Isidori AM. Curr Opin Pharmacol. 2021 Sep 7;60:298-305. doi: 10.1016/j.coph.2021.08.007. Online ahead of print. PMID: 34507030	
49.	<u>Microneedle-based nanoporous gold electrochemical sensor for real-time catecholamine detection.</u>	5.833
	Tortolini C, Cass AEG, Pofi R , Lenzi A, Antiochia R. Mikrochim Acta. 2022 Apr 7;189(5):180. doi: 10.1007/s00604-022-05260-2. PMID: 35391571	
50.	<u>Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.</u>	6.741
	Puliani G, Hasenmajer V, Simonelli I, Sada V, Pofi R , Minnetti M, Cozzolino A, Napoli N, Pasqualetti P, Gianfrilli D, Isidori AM. J Bone Miner Res. 2022 Apr 29. doi: 10.1002/jbmr.4566. Online ahead of print. PMID: 35485213	
51.	<u>Is autonomous cortisol secretion sexually dimorphic?</u>	32.069
	Pofi R , Tomlinson JW. Lancet Diabetes Endocrinol. 2022 May 6:S2213-8587(22)00110-3. doi: 10.1016/S2213-8587(22)00110-3. Online ahead of print. PMID: 35533705	

52	<u>Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial.</u> Pofi R, Giannetta E, Feola T, Galea N, Barbagallo F, Campolo F, Badagliacca R, Barbano B, Ciolina F, Defeudis G, Filardi T, Sesti F, Minnetti M, Vizza CD, Pasqualetti P, Caboni P, Carbone I, Francone M, Catalano C, Pozzilli P, Lenzi A, Venneri MA, Gianfrilli D, Isidori AM. <i>Sci Transl Med.</i> 2022 Jun 15;14(649):eabl8503. doi: 10.1126/scitranslmed.abl8503. Epub 2022 Jun 15. PMID: 35704597 Clinical Trial.	17.992
53	<u>Effects of licorice on sex hormones and the reproductive system.</u> Minnetti M, De Alcubierre D, Bonaventura I, Pofi R, Hasenmajer V, Tarsitano MG, Gianfrilli D, Poggiogalle E, Isidori AM. Nutrition. 2022 May 6;103-104:111727. doi: 10.1016/j.nut.2022.111727. Online ahead of print. PMID: 35872407 Review.	3.172
54	<u>Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study.</u> Feola T, Pirchio RS, Puliani G, Pofi R, Crocco M, Sada V, Sesti F, Verdecchia F, Gianfrilli D, Appetecchia M, Di Iorgi N, Jaffrain-Rea ML, Pivonello R, Isidori AM, Grossman AB, Sbardella E; TALENT group. J Endocrinol Invest. 2022 Aug 24. doi: 10.1007/s40618-022-01900-9. Online ahead of print. PMID: 36001286	4.632
55	<u>Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool.</u> Minnetti M, Hasenmajer V, Sbardella E, Angelini F, Simeoli C, Di Paola N, Cozzolino A, Pivonello C, De Alcubierre D, Chiloiro S, Baldelli R, De Marinis L, Pivonello R, Pofi R*, Isidori AM*. Eur J Endocrinol. 2022 Oct 13;187(5):719-731. doi: 10.1530/EJE-22-0454. Print 2022 Nov 1. PMID: 36102827	6.664
56	<u>11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.</u> Othonos N, Pofi R, Arvaniti A, White S, Bonaventura I, Nikolaou N, Moolla A, Marjot T, Stimson RH, van Beek AP, van Faassen M, Isidori AM, Bateman E, Sadler R, Karpe F, Stewart PM, Webster C, Duffy J, Eastell R, Gossiel F, Cornfield T, Hodson L, Jane Escott K, Whittaker A, Kirik U, Coleman RL, Scott CAB, Milton JE, Agbaje O, Holman RR, Tomlinson JW. Nature Commun. 2023 Feb 23;14(1):1025. doi: 10.1038/s41467-023-36541-w. PMID: 36823106	14.919
57	<u>Testicular Dysfunction in 47,XXY Boys: When It All Begins. A Semilongitudinal Study.</u> Pozza C, Sesti F, Tenuta M, Spaziani M, Tarantino C, Carlomagno F, Minnetti M, Pofi R, Paparella R, Lenzi A, Radicioni A, Isidori AM, Tarani L, Gianfrilli D. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2486-2499. doi: 10.1210/clinem/dgad205. PMID: 37043499	5.800
58	<u>Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations.</u> De Alcubierre D, Ferrari D, Mauro G, Isidori AM, Tomlinson JW, Pofi R. J Endocrinol Invest. 2023 Oct;46(10):1961-1982. doi: 10.1007/s40618-023-02091-7. Epub 2023 Apr 14. PMID: 37058223	5.400
59	<u>Pituitary adenoma consistency affects postoperative hormone function: a retrospective study.</u> De Alcubierre D, Puliani G, Cozzolino A, Hasenmajer V, Minnetti M, Sada V, Martinez V, Zaccagnino A, Ruggeri AG, Pofi R, Sbardella E, Venneri MA. BMC Endocr Disord. 2023 Apr 26;23(1):92. doi: 10.1186/s12902-023-01334-1. PMID: 37101307	3.200

60	<u>Altered Thyroid Feedback Loop in Klinefelter Syndrome: From Infancy Through the Transition to Adulthood.</u> Carlomagno F, Minnetti M, Angelini F, Pofi R , Sbardella E, Spaziani M, Aureli A, Anzuini A, Paparella R, Tarani L, Porcelli T, De Stefano MA, Pozza C, Gianfrilli D, Isidori AM. J Clin Endocrinol Metab. 2023 Oct 18;108(11):e1329-e1340. doi: 10.1210/clinem/dgad281. PMID: 37216911	5.800
61	<u>Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?</u> Pofi R , Caratti G, Ray DW, Tomlinson JW. Endocr Rev. 2023 Nov 9;44(6):975-1011. doi: 10.1210/endrev/bnad016. PMID: 37253115	20.3
62	<u>"A morning cortisol is the most effective clinical predictor of short synacthen test outcome": A tertiary care centre experience.</u> Mathara Diddhenipothage SAD, Beck KJ, Loo H, Amiyangoda GK, Pofi R , Tomlinson JW, Pal A. Clin Endocrinol (Oxf). 2023 Aug;99(2):142-151. doi: 10.1111/cen.14934. Epub 2023 Jun 8. PMID: 37288515	3.396
63	<u>Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy.</u> Pofi R , Bonaventura I, Duffy J, Maunsell Z, Shine B, Isidori AM, Tomlinson JW. Endocr Connect. 2023 Aug 2;12(9):e230059. doi: 10.1530/EC-23-0059. PMID: 37410094	2.9
64	<u>Long-term health consequences of congenital adrenal hyperplasia.</u> Pofi R , Ji X, Krone NP, Tomlinson JW. Clin Endocrinol (Oxf). 2023 Sep 7. doi: 10.1111/cen.14967. Online ahead of print. PMID: 37680029	3.396
65	<u>EMAS position statement: Testosterone replacement therapy in older men.</u> Kanakakis GA, Pofi R , Goulis DG, Isidori AM, Armeni E, Erel CT, Fistoníć I, Hillard T, Hirschberg AL, Meczekalski B, Mendoza N, Mueck AO, Simoncini T, Stute P, van Dijken D, Rees M, Lambrinoudaki I. Maturitas. 2023 Dec;178:107854. doi: 10.1016/j.maturitas.2023.107854. Epub 2023 Oct 15. PMID: 37845136	5.200
66	<u>Tall stature and gigantism in transition age: clinical and genetic aspects-a literature review and recommendations.</u> Sada V, Puliani G, Feola T, Pirchio R, Pofi R , Sesti F, De Alcubierre D, Amodeo ME, D'Aniello F, Vincenzi L, Gianfrilli D, Isidori AM, Grossman AB, Sbardella E; TALENT group. J Endocrinol Invest. 2023 Oct 27. doi: 10.1007/s40618-023-02223-z. Online ahead of print. PMID: 37891382	5.400
67	<u>Multivariable Model to Predict an ACTH Stimulation Test to Diagnose Adrenal Insufficiency Using Previous Test Results.</u> Lawrence NR, Arshad MF, Pofi R , Ashby S, Dawson J, Tomlinson JW, Newell-Price J, Ross RJ, Elder CJ, Debono M. J Endocr Soc. 2023 Oct 7;7(12):bvad127. doi: 10.1210/jendso/bvad127. eCollection 2023 Nov 2. PMID: 37942292	4.100

68	<u>Effects of Dual-Release Hydrocortisone on Bone Metabolism in Primary and Secondary Adrenal Insufficiency: A 6-Year Study.</u> Hasenmajer V, Ferrari D, De Alcubierre D, Sada V, Puliani G, Bonaventura I, Minnetti M, Tomaselli A, Pofi R , Sbardella E, Cozzolino A, Gianfrilli D, Isidori AM. J Endocr Soc. 2023 Dec 6;8(1):bvad151. doi: 10.1210/jendso/bvad151. eCollection 2023 Dec 1. PMID: 38090230	4.100
69	<u>C-Cell Hyperplasia and Cystic Papillary Thyroid Carcinoma in a Patient with Type 1B Pseudohypoparathyroidism and Hypercalcitoninaemia: Case Report and Review of the Literature.</u> Ferrari D, Pandozzi C, Filice A, Nardi C, Cozzolino A, Melcarne R, Giacomelli L, Biffoni M, Di Gioia C, Merenda E, Del Sindaco G, Pagnano A, Pofi R* , Giannetta E*. J Clin Med. 2023 Dec 6;12(24):7525. doi: 10.3390/jcm12247525. PMID: 38137593	3.900
70	<u>Copeptin and the syndrome of inappropriate antidiuresis (SIAD) after pituitary transsphenoidal surgery.</u> Efthymiadis A, Pofi R , Rostom H, James T, Shine B, Guha N, Cudlip S, Christ-Crain M, Pal A. Endocrinol Diabetes Metab. 2024 Jan;7(1):e467. doi: 10.1002/edm2.467. PMID: 38268306	2.5
71	<u>Predicting postoperative hypocortisolism in patients with non-aldosterone-producing adrenocortical adenoma: a retrospective single-centre study.</u> Bonaventura I, Tomaselli A, Angelini F, Ferrari D, De Alcubierre D, Hasenmajer V, Sbardella E, Cozzolino A, Paganini AM, Isidori AM, Minnetti M, Pofi R . J Endocrinol Invest. 2024 Feb 22. doi: 10.1007/s40618-023-02283-1. Online ahead of print. PMID: 38386266	5.4
72	<u>Development of diagnostic algorithm for Cushing's syndrome: a tertiary centre experience.</u> Efthymiadis A, Loo H, Shine B, James T, Keevil B, Tomlinson JW, Pal A, Pofi R . J Endocrinol Invest. 2024 Mar 27. doi: 10.1007/s40618-024-02354-x. Online ahead of print. PMID: 38536658	5.4
73	<u>Exploring sexual function in adrenal insufficiency: findings from the Dual Release hydrocortisone versus conventional glucocorticoid replacement therapy in hypocortisolism (DREAM) trial.</u> Hasenmajer V, De Alcubierre D, Ferrari D, Minnetti M, Bonaventura I, Pofi R , Simeoli C, Tomaselli A, Sciarra F, Bottillo G, Angelini F, Cozzolino A, Venneri MA, Jannini EA, Gianfrilli D, Pivonello R, Isidori AM. Andrology. 2024 Mar 28. doi: 10.1111/andr.13635. Online ahead of print. PMID: 38545799	4.6
74	<u>Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.</u> Sacco S, Foschi M, Ornello R, De Santis F, Pofi R , Romoli M. Diabetologia. 2024 Apr 16. doi: 10.1007/s00125-024-06146-z. Online ahead of print. PMID: 38625582	8.2
75	<u>Cardiac magnetic resonance reveals biventricular impairment in Cushing's syndrome: a multicentre case-control study.</u> Feola T, Cozzolino A, De Alcubierre D, Pofi R , Galea N, Catalano C, Simeoli C, Di Paola N, Campolo F, Pivonello R, Isidori AM, Giannetta E. Endocrine. 2024 May 22. doi: 10.1007/s12020-024-03856-7. Online ahead of print. PMID: 38775914	3.7

76	<u>Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.</u> Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, Isidori AM, Rodien P, Srirangalingam U, Kiefer FW, Falhammar H, Merke DP, Reisch N, Sarafoglou K, Cutler GB Jr, Sturgeon J, Roberts E, Lin VH, Chan JL, Farber RH; CAHtalyst Adult Trial Investigators. N Engl J Med. 2024 Aug 8;391(6):504-514. doi: 10.1056/NEJMoa2404656. Epub 2024 Jun 1. PMID: 38828955 Free PMC article. Clinical Trial.	96.2
77	<u>The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study.</u> De Alcubierre D, Feola T, Cozzolino A, Pofi R , Galea N, Catalano C, Auriemma RS, Pirchio R, Pivonello R, Isidori AM, Giannetta E. Pituitary. 2024 Aug;27(4):416-427. doi: 10.1007/s11102-024-01403-1. Epub 2024 Jun 7. PMID: 38847918 Free PMC article.	3.3
78	<u>New Approaches to the Treatment of Hypercortisolism.</u> Pofi R , De Alcubierre D, Dong J, Tomlinson JW. Annu Rev Med. 2024 Nov 1. doi: 10.1146/annurev-med-071723-044849. Online ahead of print. PMID: 39485832 Review.	15.1
79	<u>Circadian clock disruption impairs immune oscillation in chronic endogenous hypercortisolism: a multi-level analysis from a multicentre clinical trial.</u> Hasenmajer V, Sbardella E, Sciarra F, Simeoli C, Pivonello C, Ceccato F, Pofi R , Minnetti M, Rizzo F, Ferrari D, Bonaventura I, Barbagallo F, Giannetta E, Alunni Fegatelli D, Conia S, Navigli R, Arnaldi G, Scaroni C, Pivonello R, Gianfrilli D, Venneri MA, Isidori AM. EBioMedicine. 2024 Dec;110:105462. doi: 10.1016/j.ebiom.2024.105462. Epub 2024 Nov 28. PMID: 39612654 Free PMC article. Clinical Trial.	9.2
80	<u>Impact of Female Sex and Mild Cortisol Secretion on Coagulation Profile in Adrenal Incidentalomas.</u> Bonaventura I, Minnetti M, Ferrari D, Hasenmajer V, Tomaselli A, De Alcubierre D, Lenzi A, Pofi R* , Isidori AM*. J Endocr Soc. 2024 Dec 12;9(1):bvae215. doi: 10.1210/jendso/bvae215. eCollection 2024 Nov 26. PMID: 39669652 Free PMC article.	3.2
81	<u>Exploring the interplay of karyotype, hormones, sexuality, and body image perception in individuals with Turner syndrome.</u> Tarantino C, Vincenzi L, Angelini F, Tomaselli A, Carlomagno F, Rosato E, Pofi R , Lenzi A, Pozza C, Minnetti M, Spaziani M, Isidori AM, Sbardella E. J Endocrinol Invest. 2025 Feb 13. doi: 10.1007/s40618-024-02521-0. Online ahead of print. PMID: 39946049	3.9

The undersigned RICCARDO POFI is aware that false declarations lead to the application of criminal sanctions provided for by the art. 76 of the Presidential Decree 445/2000 declares that the information reported in the following curriculum vitae correspond to the true.

Place and Date
Oxford 09/03/2025

Riccardo Pofi